Long-term CD4+ and CD8+ T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16)

Launay, Odile; Surénaud, Mathieu; Desaint, Corinne; Benhamouda, Nadine; Pialoux, Gilles; Bonnet, B.; Poizot‐Martin, Isabelle; Gonzales, Gustavo F.; Bourgault‐Villada, Isabelle; Lévy, Yves; Choppin, Jeannine; Durier, Christine

doi:10.1016/j.vaccine.2013.06.102

Cited by 13 publications

(8 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering the HLA alleles of the patients and the viral CTL epitopes that should theoretically be presented, we found variability of the latter in the archived proviral DNA. This raised the question of the efficiency of curative vaccines based on generic recombinant viruses or viral peptides [17]–[18] …”

Section: Discussionmentioning

confidence: 99%

Kinetics of HIV-1 CTL Epitopes Recognized by HLA I Alleles in HIV-Infected Individuals at Times near Primary Infection: The Provir/Latitude45 Study

et al. 2014

View full text Add to dashboard Cite

In patients responding successfully to ART, the next therapeutic step is viral cure. An interesting strategy is antiviral vaccination, particularly involving CD8 T cell epitopes. However, attempts at vaccination are dependent on the immunogenetic background of individuals. The Provir/Latitude 45 project aims to investigate which CTL epitopes in proviral HIV-1 will be recognized by the immune system when HLA alleles are taken into consideration. A prior study (Papuchon et al, PLoS ONE 2013) showed that chronically-infected patients under successful ART exhibited variations of proviral CTL epitopes compared to a reference viral strain (HXB2) and that a generic vaccine may not be efficient. Here, we investigated viral and/or proviral CTL epitopes at different time points in recently infected individuals of the Canadian primary HIV infection cohort and assessed the affinity of these epitopes for HLA alleles during the study period. An analysis of the results confirms that it is not possible to fully predict which epitopes will be recognized by the HLA alleles of the patients if the reference sequences and epitopes are taken as the basis of simulation. Epitopes may be seen to vary in circulating RNA and proviral DNA. Despite this confirmation, the overall variability of the epitopes was low in these patients who are temporally close to primary infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Kinetics of HIV-1 CTL Epitopes Recognized by HLA I Alleles in HIV-Infected Individuals at Times near Primary Infection: The Provir/Latitude45 Study

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The LIPO‐4 vaccine contains four palmitoyl‐lysine associated Gag, Pol and Nef peptides covalently liked to tetanus toxin peptide (French National Agency for AIDS and Hepatitis Research VAC16 trial). The vaccine was able to induce HIV‐specific CD4+ and CD8+ responses independently of the administration route, intramuscular or intradermal . However, the intradermal route induced a weaker CD4+ response .…”

Section: Vaccinesmentioning

confidence: 97%

“…The vaccine was able to induce HIV‐specific CD4+ and CD8+ responses independently of the administration route, intramuscular or intradermal . However, the intradermal route induced a weaker CD4+ response .…”

Section: Vaccinesmentioning

confidence: 97%

HIV Vaccines: A Brief Overview

2014

View full text Add to dashboard Cite

show abstract

“…This drug inhibits the virus from infecting new cells by preventing the reverse transcription . Different types of immunotherapy were proposed for HIV infection treatment, such as DNA vaccines, mucosal vaccines, and an HIV‐lipopeptide vaccine . Generally, they have shown promising results in improving CTL response.…”

Section: Introductionmentioning

confidence: 99%

“…14 Different types of immunotherapy were proposed for HIV infection treatment, such as DNA vaccines, mucosal vaccines, and an HIV-lipopeptide vaccine. [15][16][17] Generally, they have shown promising results in improving CTL response. We introduce the effect of an immunotherapy treatment on CTL response as a controller d(t), which is assumed to be a bounded function on t ∈ [0, T] (T is the maximum time for which a unique solution of the system exists (Lemma 2)):…”

Section: Introductionmentioning

confidence: 99%

Optimal drug control in a four‐dimensional HIV infection model

Shamsara

Afsharnezhad

Effati

2019

Optim Control Appl Methods

View full text Add to dashboard Cite

Summary In this paper, we consider a four‐dimensional version of a human immunodeficiency virus (HIV) infection model, which is an extension of some previous three‐dimensional models. We approach the treatment problem by adding two controls u1 and u2 to the system for inhibiting viral production and preventing new infections. In fact, u1 is added to components of uninfected and infected cells to represent the effect of chemotherapy on the interaction of uninfected CD4+ T cells with infected cells. u2 is considered in the effector immune component as immunotherapy. The purpose of this work is to control the progress of the disease in a steady state. Hence, first, we obtain a relation between the two controls u1 and u2 such that a Hopf bifurcation occurs. Next, the Pontryagin minimum principle will be applied to derive the optimal therapy for HIV. At the end, numerical results are presented.

show abstract

Long-term CD4+ and CD8+ T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16)

Cited by 13 publications

References 57 publications

Kinetics of HIV-1 CTL Epitopes Recognized by HLA I Alleles in HIV-Infected Individuals at Times near Primary Infection: The Provir/Latitude45 Study

Kinetics of HIV-1 CTL Epitopes Recognized by HLA I Alleles in HIV-Infected Individuals at Times near Primary Infection: The Provir/Latitude45 Study

HIV Vaccines: A Brief Overview

Optimal drug control in a four‐dimensional HIV infection model

Contact Info

Product

Resources

About